Currus Biologics wins FDA IND clearance for CUR-001 CAR-T trial

Currus Biologics has received FDA clearance for its Investigational New Drug application for CUR-001, enabling the Australian company to begin its first-in-human Phase 1 trial in patients with mesothelin-positive advanced refractory solid tumours. First patient dosing is expected in early 2027.

CUR-001 is the lead programme from Currus' BEAT platform, an acronym for Bispecific Engagers of Antigen Presenting Cells and T cells. The candidate combines two components: CURB-001, a bispecific antibody, and CURT-001, a FLAG-tagged autologous CAR T-cell therapy directed against mesothelin. The bispecific antibody is intended to activate CAR T-cells in lymphoid tissue before they encounter the hostile tumour microenvironment, rather than relying on in-tumour activation alone.

Chief Medical Officer Swami Murugappan said: "CUR-001 has been designed to address some of the key biological barriers responsible for this difference by combining mesothelin-targeted CAR T-cells with BEAT-mediated immune activation. We look forward to evaluating the safety, pharmacology and early signs of clinical activity of this approach in patients with advanced solid tumours."

Why solid tumours have resisted CAR-T

CAR T-cell therapies have achieved durable remissions in haematological malignancies such as diffuse large B-cell lymphoma and multiple myeloma, but their translation to solid tumours has been consistently disappointing. The core problem is biological: solid tumours generate a profoundly immunosuppressive microenvironment that drives T-cell exhaustion, restricts infiltration and limits persistence. Mesothelin has attracted considerable interest as a target given its high expression across mesothelioma, ovarian, lung, and pancreatic cancers, but no mesothelin-directed cell therapy has yet established a clear efficacy signal sufficient to support accelerated approval.

Currus' approach attempts to sidestep exhaustion by priming CAR T-cells through antigen-presenting cells in lymphoid tissue before tumour encounter. In preclinical models, the company reports that this mechanism enhanced expansion, persistence, and tumour infiltration, while also generating epitope spreading and immunological memory. Independent academic validation is cited, though the company has not yet published full preclinical datasets in a peer-reviewed journal.

Competitive landscape and next steps

The solid tumour CAR-T space is crowded with early-stage programmes from companies including Poseida Therapeutics, Tmunity and various university spin-outs, many of which are pursuing similar strategies centred on overcoming the immunosuppressive microenvironment. Approaches in development include armoured CAR-T constructs, locally secreted cytokines, and combinations with checkpoint inhibitors. Currus' bispecific antibody add-on is positioned by the company as a modality-agnostic, platform-level solution compatible with third-party CAR-T products, which could support partnership discussions if Phase 1 generates encouraging safety and pharmacology data.

The open-label basket study design reflects the multi-tumour expression profile of mesothelin and should allow Currus to assess signals across multiple indications simultaneously, a pragmatic approach for a company of its size. Backers include Brandon Capital Partners, Main Sequence Ventures, and Uniseed, though no funding quantum or total capital raised has been disclosed in the current announcement.

Investors will focus on the Phase 1 safety readout expected to emerge through 2027 and 2028, and on whether Currus moves toward partnership deals or additional financing as it progresses toward proof-of-concept data.